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1. Introduction 
Cardiovascular disease is the worldwide major cause of mortality and morbidity. The 2009 
annual report from World Health Organization (WHO) highlighted the mortality rate 
prediction of the population worldwide that, in 2030, cardiovascular disease will become the 
major cause of deaths, and the mortality rate will higher than other infectious diseases such 
as HIV, Tuberculosis, malaria infection (World Heatlh Organization ,2009). Moreover, this 
report also mentioned that, among cardiovascular diseases, ischemic heart disease and 
cerebrovascular disease, which were reported as top 2 cause of mortality in 2004, are 
expected to still be the major cause of death in next 20 years (World Heatlh Organization 
,2009). Coronary artery disease is a sequence of pathophysiologic processes in coronary 
arteries, myocardial ischemia and infarction (Wudkowska et al.2010). Therefore, the early 
diagnostic of myocardial ischemia and infarction, will lead to the rapid and more effective of 
medical intervention, and safe the patients’ life. The standard diagnosis of coronary artery 
disease focuses on clinical assessment such as history of chest pain associated with 
electrocardiogram (ECG) changes, and elevation of cardiac specific-biochemical markers 
(Maneewong K. et al.2011).  
Determination of serum or plasma level of cardiac specific-biochemical markers is one of the 
most essential and effective way for diagnosing myocardial ischemia/infarction. The ideal 
cardiac markers should have high specificity, high sensitivity, rapidly released after the 
onset of the symptoms, abundant in cardiac tissue but less in other tissues, long half life in 
blood circulation, and capable of representing the prognosis and estimating the infarct size.  
It has been known that coronary artery disease, especially myocardial ischemia and 
ischemia-reperfusion injury is the phenomenon that related to an oxidative stress 
(Buja2005), which is an imbalance and inadequate production of reactive oxygen species 
(ROS), subsequently resulted in biochemical modifications of major principle biomolecules 
such as proteins, lipids, and nucleic acids (Valko et al.2007;Sbarouni et al.2008a;Sbarouni et 
al.2008b;Sbarouni et al.2008c;le-Donne et al.2003a;le-Donne et al.2003c). Some oxidatively 
modified biomolecules such as Ischemia Modified Albumin or IMA, has been approved by 
US Food and drug Administration (FDA) and used as a rule-out marker for acute 
myocardial ischemia (Apple et al.2005;Bar-Or et al.2000;Sbarouni et al.2008c;Sbarouni et 
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al.2008a;Sbarouni et al.2008b;Van et al.2010). In addition, many of oxidatively modified 
biomolecules have been reported to correlate with the severity of coronary artery disease 
and possibly used as a marker for myocardial ischemia (Apple et al.2005;Bar-Or et al.2001c; 
Bar-Or et al.2000;le-Donne et al.2003b;Berlett & Stadtman1997;Kiyici et al.2010;Turedi et 
al.2010; Melanson & Tanasijevic2005;Van et al.2010;Shen et al.2010;Pantazopoulos et al.2009; 
Bhagavan et al.2003;Santalo et al.2003;Sinha et al.2003;Mutlu-Turkoglu et al.2005;Mocatta et 
al.2007; Beal2002;Docherty2010;Wudkowska et al.2010;Charpentier et al.2010;Maneewong K. 
et al.2011; Sbarouni et al.2008a; Sbarouni et al.2008b;Sbarouni et al.2008c;le-Donne et 
al.2003a; le-Donne et al.2003d).  
In this chapter, studies of oxidatively modified biomolecules such as proteins, lipids, and 
nucleic acids, related to coronary artery diseases will be discussed. Moreover, clinical 
usefulness of determining these oxidatively modified biomolecules as a biomarker for 
coronary artery disease will also be addressed. 
2. Oxidative stress 
The term oxidative stress has been commonly mentioned or explained the underline 
pathophysiological mechanism of some diseases during the last thirty years (Hensley et 
al.2000). Oxidative stress is referred to an inadequate of free radicals generation and/or 
insufficient removal of the radicals by antioxidants, radical scavengers. Free radicals can 
also be defined as atoms or molecules containing one or more unpaired electrons on an open 
shell configuration (Lushchak2011), which generate the highly reactivity properties of the 
molecules. There are 2 major types of free radicals such as reactive oxygen species (ROS) 
and reactive nitrogen species (RNS). 
2.1 Reactive Oxygen Species 
Reactive oxygen species (ROS) are generated from oxygen metabolism include superoxide 
anion (O2
-), peroxyl (RO2), hydroperoxyl (HRO2
-), and hydroxyl radical (OH). In 
addition, ROS can also be non-radical species such as hydrogen peroxide (H2O2) and 
hydrochlorous acid (HOCl). ROS can be generated from regular metabolic processes or from 
external sources such as X-ray exposure, air pollutants, cigarette smoking, and etc. The 
primary source of intracellular free radicals generated by the addition of one oxygen 
electron, which is resulted in superoxide (O2
-) (equation 1). 
 O2 + e-                       O2
-  (1) 
Intracellular mechanism to balance the generation of superoxide is achieved by specific 
enzyme called superoxide dismutase (SOD), which catalyze the changing of superoxide to 
oxygen and hydrogen peroxide (H2O2) (equation 2). 
 SOD 
 2 O2
-+ 2H+                         O2 + H2O2   (2) 
This hydrogen peroxide (H2O2) that is generated from equation 2 has a property of being an 
oxidizing agent and serve as a major source of OH, which is one of the very harmful 
reactive oxygen species to the cell. According to hydrogen peroxide is non-radical and weak 
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polar, it can penetrate through the lipid bilayer of cell membrane or mitochondrial 
membrane, and destroy some biological molecules such as proteins, lipids, and nucleic 
acids. Cellular balancing mechanism for H2O2 is the enzyme catalase, which convert two 
molecules of H2O2 to oxygen and water (equation 3) 
(Catalase) 
 2 H2O2                             2H2O + O2 (3) 
Another alternative mechanism generating ROS in the cell is the Haber-Weiss reaction, 
which is a chemical catalysis of superoxide and hydrogen peroxide by ferric ion (Fe3+) to 
generate hydroxyl radical (OH) (equation 4) 
    Fe3+/CU2+ 
   O2
-  + H2O2 + O2                            OH- + 
OH (4) 
In addition, superoxide can reduce ferric ion to form ferrous ion (equation 5), the reaction 
called “Fenton reaction”. The production of ferrous ion in first Fenton reaction can react 
with H2O2 in the second reaction and result in OH- and 
OH generation (equation 6). 
 Fe3+ + O2
-                             Fe2+ + O2   (5) 
 Fe2+ + H2O2                               Fe3+ + OH- + 
OH (6) 
2.2 Reactive Nitrogen Species 
Reactive nitrogen species (RNS) are generated from the reaction of nitric oxide (NO), which 
is enzymatically generated by nitric oxide synthetase (NOS). The NOS oxidized the amino 
acid L-arginine or L-citrulline. The member of RNS include nitric oxide (NO) and nitrogen 
dioxide (NO2), as well as non radicals nitrogen species e.g. peroxynitrite (ONOO-), 
nitrousoxide (HNO2), and alkyl peroxynitrates (RONOO). Among these RNS molecules, 
NO, and ONOO- are the most investigated species, which have significant impact in 
cardiovascular complication (Kumar et al.2010). 
2.3 Antioxidants 
Antioxidants are either endogenous or exogenous compounds that prevent the generation of 
harmful free radicals, reduce the generated radicals, inactivate their harmful reactivity, and 
thereby block the chain reactions of these oxidants. The primary or chain breaking 
antioxidants so called “scavenger” which is neutralize the free radicals by donating one of 
their own electrons (Kumar et al.2010). The secondary or preventative antioxidants work by 
sequestration of transition metal ions or removal the peroxides by catalase and glutathione 
peroxidase. The tertiary antioxidants defense is the repairing of damaged molecules, in 
attempt to avoid the accumulative damages (Kumar et al.2010).  
3. The oxidative modification of biomolecules 
Reactive oxygen species readily attack a variety of important biomolecules, including 
carbohydrates, proteins, lipids, and nucleic acids. Interaction between ROS and these 
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biomolecules resulted in biochemical modifications, which alter the functions as well as the 
properties of these biomolecules (Figure 1).  
 
Fig. 1. Oxidative modification of biomolecules (Becker2004). In normal physiological 
conditions, superoxide and hydrogen peroxide are generated. Generation of intracellular 
ROS may activate the intracellular signaling pathways for cardiac protection, for example in 
ischemic preconditioning. The generated hydrogen peroxide, especially in myocardial 
ischemia, reacts with ferrous ion in Fenton reaction, which results in hydroxyl radicals. Over 
production of the hydroxyl radical causes oxidative modification of biomolecules, such as 
lipids, proteins, and nucleic acids. 
3.1 Proteins 
It has become manifested that proteins are also concerned as a target of free radical 
destruction. The mechanism involved in the oxidation modification of proteins is thought to 
occur at the monomeric level of amino acids, especially cysteine, tyrosine, phenylalanine, 
tryptophan, histidine, and methionine. The process of proteins oxidation creates new 
functional groups such as hydroxyl groups and carbonyl groups. These added up new 
functional groups can be generated by different mechanisms and can also indicate the degree 
of oxidative modification. The outcomes of the oxidative modification of proteins cause 
proteins fragmentation, cross-linking and unfolding, which may activate or hinder proteolytic 
and proteasome-mediated turnover. The biomarkers of oxidatively modified proteins include 
protein carbonyl, ischemia-modified albumin, and etc. Ischemia modified albumin (IMA) and 
protein carbonyl (PC) are oxidatively modified proteins found in many oxidative related 
disorders such as myocardial ischemia, renal ischemia, (Apple et al.2005;Pantke et al.1999;Bar-
Or et al.2000;Kiyici et al.2010;Turedi et al.2010;Melanson & Tanasijevic2005). According to this, 
many studies suggested the ability of these two oxidatively modified proteins as the early 
biomarkers for diagnosis of coronary artery disease. 
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3.2 Lipids 
Lipids are the basic biomolecules found throughout the cells, such as phospholipids 
component of the cell membrane. Therefore, lipids can be one of an oxidative modification 
targets, similar to proteins. Oxidative modification of lipids are the chain reactions, lead to 
the degradation of lipids or so-called “lipid peroxidation”, which mediated by free radicals 
abstract electrons from lipid molecules such as aldehyde group e.g. Malonaldehyde (MDA). 
Polyunsaturated fatty acids are more sensitive to the lipid peroxidation according to these 
lipids contain multiple double bonds in between methylene- CH2- groups that easily react 
with reactive hydrogen atoms (Lu et al.2010). The reactions of oxidative modified lipids 
consist of three major steps including; the initiation step, where is a fatty acid radicals are 
produced. The propagation is the direct reaction with oxygen molecules produced peroxyl 
fatty acid radials that react with another free fatty acid producing a different fatty acid 
radical and lipid peroxide or a cyclic peroxide and termination. The destruction of lipid 
molecules by lipid peroxidation can cause membrane permeability alteration, loss in 
fluidity, decreasing in electrical resistance, change in phospholipids bilayer membrane 
disruption, membrane-bound enzyme malfunction and  loose of integrity ionic gradient, 
disruption or activation of enzyme function, and cellular injury (Ayres1984). Biomarkers of 
lipid peroxidation include malonaldehyde, F2-Isoprostanes, and etc. 
3.3 Nucleic acid 
Nucleic acid is one of the basic biomolecules that play many essential roles in the cell. The 
nucleic acids-DNA and RNA- are the principal informational molecules of the living cells. 
During aging processes, free radicals such as OH can be generated and can bind to DNA 
molecules. Association and reaction of free radical to DNA can lead to DNA bases 
damaging, both purines and pyrimidines, and result in DNA strand break (Valavanidis et 
al.2009). Alteration of purines and pyrimidines play a significant role in large variety of 
pathological stages such as cancer (Kasai1997). Biomarkers of oxidative modified nucleic 
acid include 8-hydroxy-2’-deoxyguanosine, 8-nitroguanin, and etc. 
4. Oxidatively modified biomolecules as cardiac markers for coronary artery 
disease 
4.1 Ischemia modified albumin 
Generation of reactive oxygen species resulted in the modification of proteins, which 
introduce new functional groups such as hydroxyl groups and carbonyl groups (le-Donne et 
al.2003b;Berlett & Stadtman1997). Among these proteins, ischemia-modified albumin (IMA) 
was reported as an early biomarker in many pathological disorders (Kiyici et 
al.2010;Montagnana et al.2006;Abboud et al.2007;Gunduz et al.2009;Sharma et al.2007).  
Ischemia Modified Albumin (IMA) is serum albumin that modified at the N-terminal 
portion, especially at aspartate-alanine-histidine-lysine sequences, by oxidative stress 
generated during ischemia (Bar-Or et al.2001b). This modification reduced the ability of 
albumin to bind with metal ions such as cobalt, copper, and nickel (Bar-Or et al.2001a) 
(Figure 2). The ischemic mechanism initiated with the insufficiency of oxygen supply during 
ischemia, which caused cardiomyocytes cellular anaerobic metabolism. Within a few 
seconds after occlusion of a major coronary artery tissue oxygen content decreases and 
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mitochondrial oxidative metabolism becomes inhibited. At this point, a compensatory 
increase in anaerobic glycolysis for ATP production leads to accumulation of hydrogen ions 
and lactate, resulting in intracellular acidosis and inhibition of glycolysis (Reimer & 
Ideker1987). An aerobic glycolysis cannot provide sufficient ATP to meet the demand of 
myocardium. The depletion of ATP also causes the interruption of cellular ion-pumps and 
calcium influx to the cells. The excess intracellular calcium activates calcium-dependent 
proteases such as calpain, calmodulin, generates O2- and converts to H2O2. Blood consist of 
transition metals such as copper and iron, which can interact with O2- and H2O2 and form 
the strong oxidant OH, which lead to cellular destruction. Proteins, predominantly 
albumin, are damaged by free radicals especially at amino terminus (N-terminus), resulting 
in the albumin N-terminal derivatives. Human serum albumin, a major protein in 
circulation, consists of 585 amino acid residues with half life in circulation approximately 19 
days. The metal binding properties of albumin depend on the three dimensional structure 
binding sites, which are distributed over the molecule (Bar-Or et al.2001b;Takahashi et 
al.1987). The modification of albumin during ischemia is independent on cell death, and can 
be an early biomarker for such an early stage of ischemia.  
 
Fig. 2. The amino acid sequences (A) and molecular structure of albumin (B). This figure is 
modified from figure3 of Takahashi et al. (Takahashi et al.1987). Proteins albumin is 
oxidatively modified at NH2 terminal of albumin. 
Determination of serum or plasma IMA can be performed by Albumin Cobalt Binding 
(ACB) method. In 2003, US Food and drug Administration (FDA) approved that ACB 
www.intechopen.com
 
Oxidatively Modified Biomolecules: An Early Biomarker for Acute Coronary Artery Disease 
 
195 
method is the diagnostic test for acute myocardial infarction (Van et al.2010). The principle 
of ACB method is based on the principle of free radicals, which is generated during 
ischemia, alters the metal ions binding capacity of serum albumin (Sbarouni et al.2008a) 
(Figure 3). The test is currently called IMA test instead of the ACB test. It has been reported 
that IMA test could be used for screening the patients with chest pain, who suspected AMI, 
at the emergency department, excluded patients from the other causes of chest pain (Bar-Or 
et al.2000). Many studies show that IMA levels increased in patients with acute coronary 
syndrome and also elevated in myocardial ischemia (Sbarouni et al.2008a). The analytical 
sensitivity of the test is 13 u/ml, with 98% recovery (Sbarouni et al.2008a). Moreover, there 
were reports mentioned of non-interfering effect from bilirubin, hemoglobin, cholesterol, 
total proteins, and number of cardiac drugs (Govender et al.2008). It was also reported that 
no biological variation of IMA regarding race and gender (Govender et al.2008).  
According to the ability to detect IMA as a result of ischemia, the event of reduce oxygen 
supply prior to cardiomyocytes necrosis, make IMA test good enough to be an earlier 
cardiac marker (Sbarouni et al.2008a). It was reported that the serum IMA level increased 
and can be detected within 6-10 minutes after ischemia and returned back to baseline within 
6 hours (Bhagavan et al.2003). This could be an advantage of IMA, in comparison to the 
other conventional cardiac markers such as cardiac troponin and CK-MB, which are necrotic 
marker and could not be detected until 4-6 hours after onset of chest pain/ischemia (Wu et 
al.1999). Determination of IMA has been used triage patient who suspected from cardiac 
ischemia. Low level of serum IMA, would estimate low risk for a cardiac ischemic event and 
make a rapid consideration to exclude or discharge patient. Low level of serum IMA 
perhaps indirectly predicts the low level of cardiac troponin (Sbarouni et al.2008a). So, it can 
make a clear distinct when the negative results from IMA, troponin, and ECG can exclude 
the patients from ACS (Bhagavan et al.2003). The assay method can be easily and rapidly 
performed by spectrophotometric method. It has been shown that IMA test has high method 
sensitivity more than troponin as it gave positive results in 84% of patient who suspect ACS 
while cardiac troponin could detect only 42% (Takhshid et al.2010). Combination with triple 
tests including ECG, IMA, and cardiac troponin could increase the negative predictive value 
for ACS to 96% (Takhshid et al.2010). Furthermore, IMA test might reduce in the number of 
diagnostic tests such as determination of serum high sensitivity C-reactive proteins (hsCRP), 
NT-proBNP elevation, and cTnT release (Kazanis et al.2009), invasive imaging, which have 
high cost (Keating et al.2006).  
However, it seems like IMA test lack of specificity. High serum IMA level can also be 
detected in other diseases such as cancer, acute infections, end renal disease, and liver 
cirrhosis, (Kazanis et al.2009). Therefore, the negative results from cTnT test and IMA allow 
more confident to exclude the patients, who suspected AMI. However, a positive IMA alone 
still need further investigation. Moreover, it has been reported that serum IMA level can 
also be elevated in plasma from healthy subjects, 24-48 hours after exercise (Kim et al.2008). 
Therefore, utilization of IMA test as cardiac marker for coronary artery disease need to be 
further investigated to ensure the value of the test. 
4.2 Proteins carbonyl 
The carbonyl (CO) groups in proteins compose of aldehyde and ketone groups. Proteins 
Carbonyl groups (PC) is a product of oxidative modification on amino acid residues, 
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especially proline, arginine, lysine, and threonine from free radicals reactions, forming 
protein carbonyl groups [53]. In addition, protein carbonyl groups can be generated from an 
indirect mechanism of the hydroxyl radical-mediated oxidation of lipids (Figure 4). The 
product of lipid peroxidation, which will be described latter in this chapter, can diffuse 
across cell membrane, allowing the reactive aldehyde-containing lipids, which will 
covalently modified proteins in the cell (Grimsrud et al.2008). Proteins oxidation changes 
proteins functions by changing in pattern of proteins folding, which is important for their 
activity, decrease catalytic activity of enzyme, and finally breakdown of proteins by 
proteases (Almroth et al.2009). The cleavage of proteins may occur by either the amidation 
pathway or by oxidation of glutamyl side chain. Redox cycling cation such as Fe2+ or Cu2+ 
can bind to cation binding location on proteins. Free radical attack by H2O2 or O2
- can 
transform side chain of amine groups into carbonyls.  
 
Fig. 3. Principle of Albumin cobalt binding (ACB) assay. In physiological conditions, 
albumin capable of binding with metal ions such as cobalt, copper, and nickel, at amino 
terminal end of the protein. During ischemia, N-terminal portion of albumin, especially at 
aspartate-alanine-histidine-lysine sequences, is modified and result in the reduction in 
albumin-metal ions binding ability. 
Laboratory measurement of PC can be performed by variety of methods, for example, 
spectrophotometric assay, HPLC, ELISA, and immnunoblotting (le-Donne et al.2003a;le-
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Donne et al.2003b;le-Donne et al.2006). Spectrophotometric assay for PC can be perform by 
2,4-dinitrophenylhydrazine (DNPH spectrophotometric method), which based on the 
formation of a stable dinitrophenyl (DNP) hydrazone reacts in acidic pH solution. 
Spectrophotometric DNPH assay showed high sensitivity detection of carbonyl content level 
in purified proteins (le-Donne et al.2003b;Levine et al.1994). This method does not require 
any expensive or specialized equipments. It has been shown that the serum level of PC 
increased rapidly in blood stream and still remained at least 24 hours (Mutlu-Turkoglu et 
al.2005). Mutlu-Turkoglu et al. demonstrated that serum PC level increased in coronary 
artery disease, atherosclerotic lesion in human, and during ischemia-reperfusion (Mutlu-
Turkoglu et al.2005). As it has also been reported that PC can be generated following the 
onset of myocardial infarction (Paton et al.2010) suggested the diagnostic value of PC and 
may be used as biomarker for coronary artery disease. The stability of this assay remained in 
hours and days, whereas lipid oxidation products can be removed within minutes (Mutlu-
Turkoglu et al.2005). In AMI, serum PC level was significantly increased when compared 
with normal control (Paton et al.2010). Diagnosed value of PC in human can also be used in 
environmental studies, monitoring in subjects who exposed to the bunker oil (Almroth et 
al.2009). Although PC has been proven as a sensitive marker, but it was shown to has less 
specificity, similar to IMA. The increasing in serum level of PC can be detected in other 
human diseases such as Alzheimer’ disease, cataract genesis, chronic hepatitis, diabetics, 
cigarette smoker, and after doing exercise (Mutlu-Turkoglu et al.2005). According to the 
time consuming and proteins precipitation is required in spectrophotometric method, this 
technique is inappropriate to determine the PC level in large number of clinical samples. 
Therefore, other techniques, for example ELISA, were developed. Recently, the findings 
from our study demonstrated that PC could be an early marker for myocardial ischemia. 
Serum PC level in non-ST elevation myocardial infarction (NSTEMI) was significantly 
higher than that in ST elevation myocardial infarction (STEMI) and healthy controls, 
suggesting that PC is an early marker. Moreover, combinatorial determination of PC with 
IMA helps to improve the diagnostic power of these two markers (Maneewong et al.2011). 
4.3 8-hydroxy-2’-deoxyguanosine 
As mentioned in the previous section, free radicals can attack DNA and cause molecular 
structural alterations of DNA and result in DNA strand break. The interaction of OH with 
the nucleobases of DNA, such as guanine, form the C8-hydroxyguanine (8-OHGua) or its 
nucleoside form deoxyguanosine (8-hydroxy-2’-deoxyguanine) or so called 8-OH-dG. The 8-
OH-dG can be further oxidized and produced 8-oxo-7,8-dihydro-2’-deoxyguanine or 8-
oxodG (Valavanidis et al.2009) (Figure 4). Although the other nucleic acids in DNA 
molecules can react with OH in the same manner, the 8-oxodG is the major form of 
oxidative modified nucleic acids in DNA, and known as a potential biomarker of 
carcinogenesis (Kasai1997). These days, the 8-OHdG can be a biomarker of oxidative stress, 
aging and cancer. This molecule can be measured and analyzed using high sensitivity by 
high performance liquid chromatography (HPLC), gas-chromatography-mass spectrometry 
(GC-MS), and liquid chromatography-mass spectrometry- mass spectrometry (LC-MS-MS), 
immunohistochemical methods, and single cell electrophoresis (Griffiths et al.2002;Halliwell 
& Whiteman2004;Collins et al.2004). There are many reports that the elevation of 8-OHdG 
related to some pathological disorders, for example, urinary 8-OHdG has been established 
as a marker to evaluate oxidative stress in carcinogenic exposure, environment pollutants 
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and cigarette smoking (Kiyosawa et al.1990;Asami et al.1996). Elevation of 8-OHdG has been 
found in the plasma and myocardium of the patients with heart failure (Kono et al.2006). 
Recently, Himmetoglu et al. reported that the plasma level of 8-OHdG increased in patients 
with myocardial infarction and the level of this molecule decreased after reperfusion 
therapy in patients with MI, suggested that 8-OHdG could possibly be biomarker for 
monitoring or determining the prognosis of the patients (Himmetoglu et al.2009). In 
addition, Nagayoshi et al demonstrated that the urinary levels of 8-OHdG were significantly 
higher in cardiac patients when assessed the serial alteration of oxidative stress of patients 
with AMI (Nagayoshi et al.2005).  
 
Fig. 4. Mechanism of ROS stimulates lipids peroxidation induced proteins carbonylation 
(Grimsrud et al.2008). Proteins carbonylation can be induced by the oxidative modification 
of polyunsaturated fatty acids (PUFA), which then undergo to lipid peroxidation reaction 
generating products such as ,-unsaturated aldehyde 4-HNE. These molecules act as 
electrophiles in the covalently modification of proteins via non-enzymatic addition 
reactions. 
It is known that reactive nitrogen species or RNS such as nitric oxide (NO) and peroxynitrite 
(ONOO-) can modify the molecular structure of DNA (Ohshima et al.2006). The 8-
nitroguanine is the example of nucleic acid in DNA, which can be oxidatively modified by 
RNS. There is overwhelm data showed that 8-nitroguanine is undetectable in normal 
tissues, which indicating that this molecule may be a candidate as a biomarker for DNA 
damage induced by RNS (Akaike et al.2003;Ma et al.2004;Horiike et al.2005;Pinlaor et 
al.2004). Several techniques have been developed for determining 8-nitroguanine in clinical 
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samples, for example, HPLC with electrochemical detection, HPLC with a UV detector, GC-
MS, and immunohistochemistry (Halliwell & Whiteman2004;Ohshima et al.2006;Sawa et 
al.2006). Many studies showed that 8-nitroguanine increased in inflammation, 
carcinogenesis, and cigarette smoke (Hiraku2010). However, there are no any evidence of 
the increasing in 8-nitoguanine in coronary heart diseases. Therefore, further investigation 
of 8-nitoguanine in coronary heart diseases is still need to be further investigated. 
4.4 MDA 
One of the most frequently used biomarkers indicating lipid peroxidation is plasma 
concentration of malondialdehyde (MDA). This molecule is one of the end products of lipid 
peroxidation in the cell membrane or in low-density lipoproteins (LDL) (Ogino & 
Wang2007). Quantification of plasma MDA level can be performed by thiobarbituric acid 
(TBA) test (Nielsen et al.1997). TBA-reactive substances (TBARS) formed in plasma, urine, or 
tissue samples that need to be calibrated by sample pretreatment procedure, which forms a 
red adduct with 2 molecules of TBA (MDA-TBA2). The adducted compounds are separated 
by an HPLC method, which originally described by Wong et. al.(Wong et al.1987) and 
Carbonneau et. al. (Carbonneau et al.1991). The GC-MS method has been used to analyze the 
plasma MDA as well (Yeo et al.1994). It has been reported that the plasma from patients 
with coronary artery disease also had higher level of MDA than the healthy subjects, 
suggested that MDA could be one of the candidate biomarkers for coronary artery disease 
(Rajesh et al.2011;Rao & Kiran2011;Mogadam et al.2008;Pasupathi et al.2009). A recent 
report also suggested that serum levels of TBARS, which was determined by reverse-phase 
HPLC and spectrophotometric method, were a good predictive marker in patients with 
stable coronary artery disease (Walter et al.2004). 
4.5 F2-Isoprostanes 
Isoprostanes are a complex family of compounds generated from arachidonic acid via a free 
radical’s catalyzed mechanism. This compound was firstly discovered in 1990 by Morrow et. 
al. who discovered prostaglandin-F2-like compounds, and termed this newly discovered 
compound as F2-isoprostanes (Morrow et al.1990). The F2 -isoprostanes can be generated by 
the oxidative induced peroxidation of arachidonic acid (Figure 5).  
Determination of F2-isoprostanes is similar to other techniques measuring the products from 
lipid peroxidation including GC-MS, which might be associated with an immunoaffinity 
extraction, GC-tandem MS, and LC-tandem MS (Halliwell2000). Although these techniques 
have high specificity, the budget cost of these techniques is the impediment of their routine use 
(Milne et al.2005). Determination of 15- F2t-IsoP in urine samples, by radioimmunoassay, has 
been validated and easier alternative to GC-MS. In addition, the new technique is developed, 
for example enzyme-immunoassay for detecting F2-isoprostanes (Milne et al.2005). 
F2-isoprostanes can be measured in varieties of clinical samples, for example urine, plasma, 
bronchoalveolar lavage fluid, bile, cerebrospinal, seminal and pericardial fluids (Iuliano et 
al.2001;Lindsay et al.1999;Delanty et al.1997;Cipollone et al.2000;Reilly et al.1997). In 
addition, F2-isoprostanes can be detected in normal tissues, including umbilical cords (Chu 
et al.2003). The level of F2-isoprostanes increased in cigarette smoking, similar to other 
oxidative modified molecules, which is known that the increasing in smoking can cause the 
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oxidative stress (Reilly et al.1996;Morrow et al.1995). The measurement of isoprostanes in 
biological fluids has prompted clinical investigations on the pathophysiological role of lipid 
peroxidation in cardiovascular diseases. In coronary artery disease, the quantified 
isoprostanes was mostly in 15- F2t-IsoP and 5- F2t-IsoP, which can be measured in urine 
samples (Haschke et al.2007). The urinary level of 15- F2t-IsoP and 5- F2t-IsoP was found to 
increase in, unstable angina, reperfusion following myocardial infarction and 
cardiopulmonary bypass, coronary angioplasty (Sakamoto et al.2002). These findings 
suggested that isoprostane could be biomarker for coronary artery disease.  
 
Fig. 5. The Chemical reaction of 2’-deoxyguanosine with hydroxyl radicals. The Oxidative 
modification reactions of 2’-doxyguanosine cause by hydroxyl radicals. This radical adducts 
are oxidized to 8-hydroxy-2’-deoxyguanosine (8-OHdG), or it tautomer 8-oxo-7-hydro-2’-
deoxyguanosine (8-oxodG). 
4.6 Advanced Glycation End-Produces (AGEs)  
Advanced glycation end-produces (AGEs) are products of non-enzymatic glycation of 
proteins by reducing sugars (Zieman & Kass2004). AGEs was firstly discovered in early of 
1900s by Louis Camille Mailard by the non-enzymatic chemical reaction between reducing 
sugars and amino groups on proteins to form protein-protein crosslink and complex yellow-
brown pigments (Zieman & Kass2004). The Maillard reaction occurs when the reducing 
sugars, such as glucose, react with an amine groups, result in the formation of an unstable 
Shift bases (Figure 6).  The produced unstable Shift bases that transform to an Amadori 
product, which can further rearrange to form advanced glycation endproducts (AGEs) 
capable of crosslinking proteins (Figure 7, 8). 
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Fig. 6. Metabolic pathways of isoprostane (Cracowski & Durand2006). Free radicals interact 
with arachidonic acid produce arachidonyl radicals; these molecules were continue to the 
lipids peroxidation reaction and generated four types of prostaglandin-H2-like compounds, 
which subsequently reduced to be 4 prostaglandin F2.  
 
Fig. 7. The Maillard reaction is chemical reaction between a reducing sugar, such as glucose, 
and amino acid groups. The outcome from this reaction is the formation of unstable Schiff 
bases that can transform to an Amadori products, which can rearrange to form advanced 
glycation endproducts (AGEs) (Zieman & Kass2004). 
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Fig. 8. The formation of collagen-collagen-AGEs crosslinking, this figure was modified from 
Zieman et. al. AGEs from the Maillard reaction can accelerate enzymatically crosslinking 
reaction of collagens strands (Zieman & Kass2004).  
It has been known that AGEs play important role in the pathogenesis of diabetic vascular 
complications, as they lead to an abnormal leakage of proteins from the circulation and a 
progressive constriction of the luminal area of vessel (Brownlee et al.1988;Makita et 
al.1991;Ono et al.1998). Moreover, AGEs have been recognized as factors in the pathogenesis 
of other diabetic complications, such as nephropathy and retinopathy (Makita et al.1991;Ono 
et al.1998). In addition, the level of serum concentration of AGEs was associated with 
severity of coronary arthrosclerosis and development of this pathology in type 2 diabetic 
patients (Kiuchi et al.2001). Interestingly, it has been reported that the serum level of AGEs 
were elevated and correlated significantly with oxidized LDL, especially in diabetic patients 
(Lopes-Virella et al.2011). A recent evidence of 18-year study showed that the serum level of 
AGEs could predict the mortality from cardiovascular disease and coronary heart disease in 
non-diabetic women (Kilhovd et al.2005). 
Determination of AGEs is similar to other techniques, used in determining other oxidative 
modified biomarkers, such as HPLC, GC-MS, ELISA, and immunochemistry (Ogino & 
Wang2007). The accuracy and reproducibility of these techniques have not been well 
examined according to lack of universally established unit of measurement, for comparing 
study findings from different laboratories (Ogino & Wang2007). Furthermore, AGEs has 
been reported to increase in cigarette smoking, similar to the findings found in other 
biomarkers (Nicholl & Bucala1998). 
5. Early cardiac biomarkers for diagnostic acute coronary syndrome 
The biochemical markers have been routinely used to assess myocardial damage, especially 
in patients suspected with ACS. World health organization criteria, formulated in 1979, have 
classically diagnosed in ACS patients if the patient present two (probable) or three (definite) 
diagnostic criteria of acute coronary syndrome. The criteria including clinical history of 
ischemic type chest pain lasting for more than 20 minutes, changes in serial ECG tracings, 
and elevation of serum cardiac biomarkers. Patients with ACS are subdivided into the 
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following 2 major categories based on the results from electrocardiogram (ECG) including 
those whose ECG show ST-elevation that is diagnostic of acute ST-elevation myocardial 
infarction (STEMI) and those who present other patterns of ECG change, but not categorized 
in STEMI, called non- ST elevation ACS (NSTEACS). The latter include unstable angina 
(UA) and non-ST-elevation myocardial infarction (NSTEMI) (Morrow et al.2007;Wiviott & 
Braunwald2004). The ECG in NSTEMI can be interpreted in the way that the artery is only 
partially blocked, or only transiently occlusive, and results in coronary ischemia without the 
appearance of ST-segment elevation. The ECG is the most readily available tool for 
diagnosing STEMI. However, the limitation of ECG is usually occur in acute chest pain, 
according to the low sensitivity of the baseline ECG, which is only 60% (Panteghini2002). 
Undetectable of ST-elevation of ECG lead to delay in final diagnosis and affect treatment 
and clinical outcome. Therefore, determination of high sensitivity, specificity and early 
ischemic biomarker is useful for diagnosis of acute myocardial ischemia, particularly in 
NSTEMI patients. There are many types of conventional cardiac biomarkers such as creatine 
kinase- MB isoenzyme (CK-MB), cardiac troponin I or T (cTnI, cTnT). These conventional 
cardiac markers are known to release in blood circulation as a result of cellular necrosis, not 
early enough to detect the early phase of myocardial ischemia that may not excess the 
reference range of biochemical markers of myocardial necrosis. Determination of 
plasma/serum cardiac biomarkers in patients, who has arrived hospital after the onset of 
symptoms, may not be detected. Therefore, screening method, for measuring the early 
cardiac biomarkers that actually reflect the early phase of cellular injury, is extremely useful. 
The more rapid diagnosis, the more effective intervention and treatment, the less cost for 
hospital stay, secondary prevention and reduce effective budget for screening test to exclude 
myocardial infarction patients (Figure 9) 
Creatine kinase (CK) is an enzyme responsible for transferring a phosphate group from ATP 
to creatine. The molecular weight of this enzyme is approximately 80,000 dalton. It is 
composed of M and/or B subunits build up at least 3 isoenzymes including CK-BB, CK-MB, 
and CK-MM or CK-1, CK-2 and CK-3, respectively.  Moreover, there are one more 
isoenzymes that have been reported e.g. mitochondrial isoenzyme. CK-2 or CK-MB is 
sometime called the cardiac isoenzyme as it is predominant isoenzyme in myocardium, 
whereas there is only 2-5% in skeletal muscle. CK-MB can be found in large amount of 
infarcted myocardium and can rise up in the circulation within 3-6 hours after ischemia, 
peaks in 10-48 hours, and returns to normal within 72 hours (Wu et al.1999). However, an 
elevated serum CK-MB may occur in people with severe skeletal muscle damage (such as in 
muscular dystrophy, accident) and renal disease (Green et al.1986). In such cases, the ratio of 
CK-MB per total CK, or CK index, is very helpful. If the index is under 4%, a non-
myocardial source of high CK-MB should be concerned. One of the limitations of 
determining serum CK-MB is undetectable of minimal myocardial injury, late rise in the 
setting of AMI.  
Cardiac Troponin is a useful cardiac marker, localized in myofibrils. Troponin consists of 3 
subunits including inhibitory subunit (cTnI), calcium binding subunit (cTnC), and 
tropomyosin binding subunit (cTnT). The troponin complex is located on the thin filaments 
of the contractile muscles and regulates the calcium mediated interaction of myocardial 
myosin and actin filaments. The specificity, sensitivity, and reliability of troponin assay for 
diagnosed myocardial necrosis make cardiac troponin be an ideal cardiac marker. In 
addition, the minimal concentration in serum cardiac troponin, from healthy people without 
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cardiac disease, cannot be detected (Adams, III et al.1993). Among those 3 forms of cardiac 
troponin, troponin C cannot be used as cardiac marker according to non-specific expression in 
various tissues, not only the heart (Adams, III et al.1993). Cardiac troponin I (cTnI) and cardiac 
troponin T (cTnT) are 2 forms that normally used as cardiac marker. It has been known that, 
after myocardial ischemia, elevated cTnT last for 10 days to 2 weeks. The advantages of cTnT 
include highly sensitive for detecting MI, cTnT level may also help to risk stratify afterward, 
qualitative test run in 10 minutes. In contrast, the disadvantage of using cTnT assays as cardiac 
markers due to non specificity of cTnT, which can be found in unstable angina, chronic renal 
failure (Wood et al.2003). The cTnI is also being an ideal marker for ACS, according to high 
sensitivity and specificity of this marker in AMI. However, these two markers could not 
counted as the early marker, as it need  increase around 6 hours after ischemia, until the level 
of cTnT is significantly higher than normal level. 
The oxidatively modified markers such as PC and IMA have been proven as potential 
cardiac marker for diagnosis of ACS. However, determining of oxidative modified markers 
is not specific for myocardial ischemia. For example,  it has been reported that the plasma 
level of IMA can be increased in cerebral, gastrointestinal intestinal and skeletal muscular 
ischemia as well as myocardial ischemia (Matthews et al.1990;Siegel et al.1995). Therefore, it 
is recommended that the interpretation of a positive IMA finding should be combined with 
other clinical indices (Shen et al.2010). Recently, our study showed the usefulness of 
determining serum IMA and PC content level to identify acute myocardial infarction, 
particularly in STEMI. The level of both serum IMA and PC content were significantly 
higher in STEMI compared to healthy control and determination of serum IMA level in 
combination of serum PC content level improved test performance (Kumphune et al.2010). 
However, the results from our recent study reported that diagnosis of NSTEMI was not 
improved by combination of serum IMA and PC level, in contrast, individual determination 
of serum PC content showed a good area under ROC curve and high PPV for NSTEMI 
diagnosis (Maneewong et al.2011). Charpentier et. al. also demonstrated in a large cohort 
study of patients admitted to an emergency department  for chest pain that IMA did not 
provide valuable information for ACS diagnosis (Charpentier et al.2010). The possible 
explanation is NSTEMI patients did not have major myocardial necrosis, unlike in patients 
with STEMI. Therefore, the minor myocardial damage possibly has less degree of ROS 
mediated proteins oxidation. 
Another limitation of using oxidative modified biomarkers is the interpretation in elder 
patients. It has been reported that oxidative modified forms of proteins were accumulated 
during aging (Berlett & Stadtman1997). For example, increases in proteins carbonyls occur 
in rat hepatocytes, drosophila, brain, and kidney of mice and in brain tissue of gerbils 
(Beal2002). In humans proteins carbonyls increase with age in brain, muscle, and human eye 
lens (Beal2002). The carbonyl content of human fibroblasts also increases as a function of age 
of the donor (Beal2002).  
There are some reports determining other oxidative modified molecules, such as 8-OH-dG, 
isoprostane, and AGEs, in ACS. However, those reports were indicated only the incidences 
of elevated markers in ACS, but not the efficiency of the test. Therefore, determination of 
analytical method efficiency of those markers is challenge and need to be further 
investigated. 
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Fig. 9. The kinetics curve of conventional biomarkers. The rise and fall pattern of 
conventional cardiac biomarkers such as myoglobin, CK-MB, and cTnT. These markers 
release to circulation many hours after the onset of chest pain, post ischemia. Novel early 
markers, probably oxidatively modified markers, which release into blood stream, right 
after the onset of ischemia, will helpful. 
6. Conclusion 
Early cardiac biomarkers are essential for diagnosis of acute coronary syndrome. 
Conventional markers might not early enough to detect the early phase of cellular injury 
according to ischemia. Many oxidatively modified biomolecules were studied and known to 
have potential as cardiac markers. Further intensive investigation of these cardiac markers, 
especially the diagnostic power, is very helpful and can be used in real clinical investigation 
of coronary artery disease. 
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